European Innovation Council

Chipiron develops portable MRI technology that uses quantum sensing to produce three-dimensional anatomical images at ultra-low magnetic fields. The devices are lightweight, portable, and priced at about one-tenth of conventional MRI systems. The technology supports disease detection, diagnosis, and treatment monitoring, with a focus on brain-related conditions, and aims to reduce fatality rates by expanding access to MRI imaging in diverse clinical settings.

AMT Medical B.V., established in 2015 and located in Ede, the Netherlands, specializes in the development of innovative medical devices for heart bypass surgery. The company's flagship product, the AMT Heart Bypass System, utilizes a minimal invasive technique known as the ELANA bypass, which was invented by neurosurgeon Prof. Dr. C.A.F. Tulleken and his research team. This advanced technology aims to enhance traditional heart bypass procedures by making them faster, safer, and less invasive, thereby improving patient outcomes and reducing complications. AMT Medical has completed the full development of its product and the production process, with all pre-clinical trials successfully concluded. The company is also preparing to initiate a clinical multi-center trial to further validate the technology's efficacy.

Precisionlife employs a unique approach to drive innovation in chronic diseases through precision medicine. It uses artificial intelligence to generate deep insights into disease biology, stratifying patient populations for novel drug targets, biomarkers, and repositioning candidates.

Founded in 2012, Stablepharma specializes in developing processes for vaccine stabilization. Its flagship product, Stablevax, enables precise dosage pre-loading into syringes at manufacture, eliminating wastage. The company's technology platform converts existing vaccines and diagnostics into thermostable products, addressing global cold chain challenges.

QDI Systems B.V. is a startup based in Groningen, the Netherlands, focused on developing advanced imaging devices for medical applications using quantum dot technology. The company specializes in creating X-ray sensors that deliver high-contrast and high-resolution imaging, particularly for mammography, while also reducing radiation exposure for patients. QDI Systems aims to provide user-friendly quantum dot materials accompanied by comprehensive instructions for constructing high-performance imaging devices. By leveraging innovative technology, the company enhances the precision of medical imaging, enabling healthcare professionals to obtain critical diagnostic information efficiently and safely.

QDI Systems B.V. is a startup based in Groningen, the Netherlands, focused on developing advanced imaging devices for medical applications using quantum dot technology. The company specializes in creating X-ray sensors that deliver high-contrast and high-resolution imaging, particularly for mammography, while also reducing radiation exposure for patients. QDI Systems aims to provide user-friendly quantum dot materials accompanied by comprehensive instructions for constructing high-performance imaging devices. By leveraging innovative technology, the company enhances the precision of medical imaging, enabling healthcare professionals to obtain critical diagnostic information efficiently and safely.

AlzeCure Pharma is a Swedish pharmaceutical company dedicated to developing drug therapies targeting diseases affecting the central nervous system. Its primary focus lies in Alzheimer's disease, with five drug candidates at various stages of development.

Elicera Therapeutics is a clinical-stage immuno-oncology company based in Sweden that focuses on developing innovative cell and gene therapies to treat cancer. The company’s portfolio includes four drug candidates: two oncolytic virus therapies, ELC-100 and ELC-201, and two CAR T-cell treatments, ELC-301 and ELC-401. Additionally, Elicera has developed a universal CAR T-cell technology platform named iTANK (ELC-001), designed to enhance the efficacy of CAR T-cell therapies by enabling a multi-targeted approach against solid tumors. With its commitment to advancing immune-based cancer treatments, Elicera Therapeutics aims to improve outcomes for patients facing various forms of cancer.

Aplagon is a biopharmaceutical company focused on the development of innovative antithrombotic compounds aimed at addressing unmet medical needs in patients experiencing complications from vascular interventions. The company specializes in creating biological mimetics of heparin proteoglycan, which are designed to effectively manage thrombotic occlusions and ischemic reperfusion injuries associated with vascular injuries. By prioritizing safety and efficacy, Aplagon seeks to deliver antithrombotic therapies that offer significant advantages over existing treatments, ultimately improving patient outcomes in challenging medical scenarios.

TENSIVE s.r.l. is a biomedical company based in Milan, Italy, founded in 2012. It specializes in the development of innovative prostheses for natural breast reconstruction and augmentation. The company's products utilize biodegradable synthetic biomaterials and feature an internal micro-architecture that mimics blood vessel structures. These vascularized prostheses aim to enhance the quality of life for patients undergoing treatment for breast cancer, offering a solution that reduces the need for recurrent and costly surgical interventions. Through its focus on advanced biomaterials and design, TENSIVE seeks to provide effective and sustainable options for breast reconstruction.

Patient-specific right heart pumps that free patients from heavy battery packages and increase patient's quality of life.

Acorai develops a non-invasive heart failure monitoring platform centered around direct intracardiac pressure monitoring. Its patented technology combines sensor technologies and machine learning to enable accurate, cost-efficient care, reducing re-hospitalization and mortality rates.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

Quantune Technologies is a deep tech startup specializing in optics and photonics technology. The company focuses on developing advanced infrared spectrometers that facilitate continuous and non-invasive health monitoring. By miniaturizing traditional laboratory equipment used for molecular analysis into compact modules, Quantune enables both biomedical consumer devices and industrial applications. This innovation allows clients to efficiently conduct real-time monitoring and analysis of chemical compounds and emissions, providing accessible solutions for a range of novel applications.

Innoventric is an Israeli medical device company specializing in percutaneous solutions for Tricuspid Regurgitation and right heart disease. Founded in 2017, the company's flagship product is the Trillium™ technology, designed to treat Tricuspid Valve Regurgitation through functional valve replacement using Cross-Caval anchoring and a unique multi-valve design.

Inbrain Neuroelectronics is a medical device company that designs and commercializes graphene-based neural interfaces and intelligent neuromodulation systems to treat brain disorders. The core platform is an implantable system that decodes brain activity with high resolution and provides focal, adaptive stimulation, enabling real-time precision neurology and autonomous therapy adjustments. This approach aims to maximize therapeutic outcomes while minimizing side effects for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. The company pursues strategic collaborations to extend its solutions to peripheral nerve and systemic disease applications, expanding the potential of neurotechnology and bioelectronics.

MediWound Ltd. is an integrated biopharmaceutical company based in Yavne, Israel, that specializes in developing, manufacturing, and commercializing innovative therapeutic products for severe burns and chronic wounds. Founded in 2000, the company is known for its flagship product, NexoBrid, which is an FDA-approved biopharmaceutical designed for the removal of eschar in adults with deep partial- and full-thickness thermal burns, offering a less invasive alternative to surgical interventions. MediWound also advances other product candidates, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic and hard-to-heal wounds, and MWPC003 for connective tissue disorders. The company aims to address significant unmet medical needs in these areas and improve patient outcomes.

MediWound Ltd. is an integrated biopharmaceutical company based in Yavne, Israel, that specializes in developing, manufacturing, and commercializing innovative therapeutic products for severe burns and chronic wounds. Founded in 2000, the company is known for its flagship product, NexoBrid, which is an FDA-approved biopharmaceutical designed for the removal of eschar in adults with deep partial- and full-thickness thermal burns, offering a less invasive alternative to surgical interventions. MediWound also advances other product candidates, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic and hard-to-heal wounds, and MWPC003 for connective tissue disorders. The company aims to address significant unmet medical needs in these areas and improve patient outcomes.

Endoron Medical develops a catheter-based device to secure endografts during endovascular aneurysm repair. The treatment uses a stapling mechanism that mimics hand-sewn suturing by deploying multiple staples around the aortic circumference to achieve transmural attachment of the stent graft to the aortic wall. The device aims to reduce endoleaks and graft migration and to enable treatment of complex abdominal aortic aneurysm anatomies by improving fixation and sealing of the endograft.

UroMems is a medical device company dedicated to addressing specific clinical needs related to urinary conditions that significantly impact patients' quality of life. The company specializes in the design, development, and commercialization of active implantable medical devices. Its innovative approach aims to enhance existing surgical treatments by minimizing associated side effects and ensuring that patients receive appropriate care promptly. Through its commitment to improving treatment options, UroMems seeks to benefit a wide range of patients facing urinary health challenges.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

King's College London is a public research university in London, United Kingdom, and a constituent college of the University of London. Founded in 1829 by King George IV and the Duke of Wellington, it operates from multiple central London campuses and a campus in Denmark Hill, with a strong emphasis on medical and biomedical research and education. The institution supports a large community of students and staff and is known for its extensive graduate and postgraduate programmes. It is a founding member of the King's Health Partners academic health sciences centre and participates in major research and academic networks, including the Russell Group and Universities UK.

Vitestro develops autonomous blood drawing technology aimed at transforming patient care.

Vitestro develops autonomous blood drawing technology aimed at transforming patient care.

Sentante is a medical technology company specialising in the development of robotic teleoperated systems for endovascular procedures. Their core product enables physicians to perform complex surgeries remotely, reducing their exposure to harmful X-rays and expanding telesurgery capabilities.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing innovative treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating novel antibacterial resistance-breakers, including stand-alone inhibitors of bacterial metalloenzymes. These inhibitors are designed to be combined with existing antibiotics, such as carbapenems, to restore their efficacy against the most challenging pathogens responsible for life-threatening infections, including carbapenem-resistant nosocomial pneumonia. Antabio aims to address significant unmet medical needs in the treatment of drug-resistant infections, ultimately providing healthcare professionals with effective medicinal products to combat these critical health challenges. The company has been recognized for its work, receiving a Wellcome Trust Seeding Drug Discovery Award.

RespiQ is a healthtech company developing portable, non-invasive breath analysis technology that uses emission spectroscopy and artificial intelligence to detect biomarkers in breath for early identification and real-time monitoring of respiratory diseases such as COPD, as well as other conditions like asthma, lung cancer, and infectious diseases. Its device aims to be affordable and user-friendly, democratizing access to advanced diagnostics, while its platform can also identify digestive issues through breath biomarkers and support personalized guidance via an app that analyzes a digital breath print to deliver diet and health insights, enabling individuals to monitor changes and improve health outcomes.

Methinks is a developer of a medical imaging platform that leverages advanced artificial intelligence techniques to enhance the diagnosis of brain-related diseases, particularly acute stroke. Utilizing Google's deep learning framework, Tensorflow, Methinks analyzes neuroimaging data to facilitate accurate and timely diagnoses. The platform offers a significant advantage by enabling stroke assessments through non-contrast CT scans, thereby eliminating the need for contrast CT and reducing the time required for treatment. This innovative approach enhances communication between radiologists, hospitals, stroke units, and other healthcare professionals, ultimately aiming to improve clinical outcomes in stroke care.

NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.

Acorai develops a non-invasive heart failure monitoring platform centered around direct intracardiac pressure monitoring. Its patented technology combines sensor technologies and machine learning to enable accurate, cost-efficient care, reducing re-hospitalization and mortality rates.

ResoTher Pharma is a privately held biotechnology company based in Copenhagen, Denmark. The company specializes in developing peptide-based drugs derived from Annexin A1, an endogenous immunomodulator. These drugs are designed as resolution therapies for diseases where neutrophil-driven inflammation is a key pathological factor. ResoTher Pharma's primary focus is on addressing cardiovascular and inflammatory disorders that have significant unmet medical needs. Their patented peptide drugs target a G-protein coupled receptor expressed on leukocytes, aiming to mimic the body's natural response to resolving inflammation and promoting tissue repair.

Founded in 2017, SolasCure is a biotechnology company based in Wales, UK. It specializes in developing innovative hydrogel treatments for patients with chronic wounds. Its flagship product, Aurase, facilitates wound debridement, removing dead or infected tissue to enhance healing.

Founded in 2014, Cellevate specializes in developing advanced 3D cell culture systems using nanofiber technology. Its patented platform enables the creation of consistent and porous networks of nanofibers, serving as realistic in-vitro models for scientific research and development across various industries.

Epigene Labs SAS is a biotechnology firm focused on enhancing precision oncology through its advanced technology platform that utilizes artificial intelligence. Founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, the company addresses the significant challenges of aggregating, analyzing, and visualizing extensive genomic data in cancer research. By integrating proprietary data from partners with publicly available datasets, Epigene Labs provides medical researchers with actionable insights and user-friendly analytics. The company collaborates with leading cancer centers and prominent biotech firms to develop intelligence-augmenting services that support drug discovery and research in precision oncology. Its innovative approach aims to transform genomic data into effective strategies for targeted cancer therapies.

EyeControl is a medical technology company specializing in innovative communication solutions for healthcare. It develops devices that enable patients, particularly those with limited mobility or speech impairments, to communicate using eye movements. The company's flagship product is an intensive care unit communication device featuring an infrared camera and a connected computer that translates blinks and eye movements into commands.

Innitius specializes in developing diagnostic devices aimed at enhancing women's health, particularly in the context of preterm birth. Utilizing innovative torsional ultrasound technology, the company has created a patented intravaginal probe that transmits torsional waves to assess changes in tissue consistency. This technology enables medical practitioners to evaluate the risk of preterm birth and the likelihood of successful labor induction. By providing actionable diagnostics, Innitius helps healthcare providers accurately identify false indications of premature labor, thereby improving patient care and outcomes in obstetrics.

Ligence is a Deep Tech startup based in Lithuania that combines medical expertise with artificial intelligence to automate echocardiography image analysis. The company develops tools for automatic recognition of heart image views, measurement, and report generation, accessible via a web-based platform and designed to integrate with hospital information systems. Its flagship solution, Ligence Heart, aims to reduce manual measurements by physicians and enhance consistency in heart ultrasound examinations through automated analysis. The offering targets clinicians and healthcare providers seeking to streamline cardiovascular imaging workflows.

RUBYnanomed provides non-invasive monitoring of cancer progression. They enable the analysis of their phenotypic, genetic, and functional characteristics, facilitating unprecedentedly frequent monitoring of cancer progression in a minimally invasive, cost-efficient way. They enable oncologists to detect and analyze the evolution of cancer subtypes and therapeutic resistance mechanisms in each patient, providing personalized therapy insights to treat their patients.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

Inbrain Neuroelectronics is a medical device company that designs and commercializes graphene-based neural interfaces and intelligent neuromodulation systems to treat brain disorders. The core platform is an implantable system that decodes brain activity with high resolution and provides focal, adaptive stimulation, enabling real-time precision neurology and autonomous therapy adjustments. This approach aims to maximize therapeutic outcomes while minimizing side effects for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. The company pursues strategic collaborations to extend its solutions to peripheral nerve and systemic disease applications, expanding the potential of neurotechnology and bioelectronics.

Rockfield Medical Devices is a forward-thinking small to medium enterprise focused on human-centered design within the medical device sector. Founded by an industry expert, the company comprises a team of recognized professionals from medical device research and design. Rockfield is dedicated to becoming a global leader in the enteral feeding market, aiming to enhance user satisfaction through innovative, plug-and-play technologies that prioritize design, usability, and mobility. The company's platform significantly improves the mobility and quality of life for individuals relying on tube feeding, while also streamlining technical support and reducing maintenance costs for sales partners. By offering a user-friendly, lightweight, and discreet mobile feeding system, Rockfield Medical Devices seeks to transform service models in the enteral feeding community.

Pulse is a platform for furthering our understanding of bioprinting and its applications in space exploration and medicine.

Trisol Medical is a medical device company focused on addressing tricuspid regurgitation through innovative treatment solutions. The company specializes in the development of a transcatheter tricuspid replacement valve, which is engineered from a nitinol frame and features specially designed leaflets. This design effectively eliminates tricuspid regurgitation while preserving the function of the right ventricle. Trisol Medical's offerings aim to provide comprehensive treatment for patients suffering from tricuspid regurgitation and associated right ventricle dysfunction, enhancing patient outcomes and quality of life.

Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.

Handiscover Sweden AB is an online booking platform specializing in accommodations for individuals with physical disabilities. Founded in 2014 by Sebastien Archambeaud in response to personal experiences as a parent of a child with a muscle disease, the company is headquartered in Malmö, Sweden. Handiscover features a distinctive classification system that allows users to select accommodations based on varying levels of mobility and physical needs. This community-based platform not only enables individuals with disabilities to find suitable vacation rentals but also assists companies and municipalities in gathering and presenting essential accessibility data. By focusing on the unique requirements of its users, Handiscover aims to enhance the travel experience for people with disabilities, making it easier for them to discover and book accessible holiday accommodations.

Elgan Pharma is a biotechnology company specializing in neonatology, primarily focused on addressing the medical challenges faced by premature infants. The company develops innovative therapies using nanotechnology aimed at preventing visual impairment, a significant concern for preterm babies. By targeting the multifactorial causes of visual disabilities, Elgan Pharma enables healthcare professionals to improve visual outcomes and reduce the risk of long-term disabilities in this vulnerable population. Through its advancements in late-stage development, the company is committed to enhancing the quality of care for premature infants and addressing critical developmental difficulties associated with their early birth.

Aviwell is a company focused on enhancing animal health and growth through the development of natural and sustainable solutions. Utilizing a microbiota-based platform powered by artificial intelligence and machine learning, Aviwell operates at the intersection of digital and life sciences. The company aims to provide insights that improve animal health and performance while addressing the agri-food industry's challenges in sustainably feeding a growing global population. By prioritizing health and sustainability, Aviwell seeks to offer effective solutions at a reduced cost, ultimately contributing to better nourishment for the planet.

Neuro Event Labs Oy, established in 2015 and headquartered in Tampere, Finland, specializes in developing artificial intelligence-based software for epilepsy patient monitoring. Their primary product collects accurate seizure data from patients at home and in hospitals, which is then analyzed and relayed to physicians for informed treatment decisions. This solution was developed in close collaboration with leading Finnish hospitals.

Cellbox Solutions is a technology company that specializes in innovative logistic solutions for the global BioMed industry. It has developed a carbon dioxide incubator designed for the storage, isolation, handling, and analysis of biological materials. This incubator offers essential logistic services and ensures the proper handling of living cells, facilitating their storage, reproduction, transportation, and analysis. By enabling the transportation of living cells via various methods, including road, rail, and air, Cellbox Solutions supports healthcare providers in their efforts to deliver the latest therapies to patients.

Plasmacure develops a cold plasma technology to treat chronic wounds, with a focus on diabetic foot ulcers. Based in Eindhoven, the Netherlands, the company aims to stimulate healing by killing bacteria, promoting cell proliferation, and improving microcirculation, thereby reducing the risk of amputation and enhancing patient quality of life.

Carthera is a clinical-stage medtech company focused on developing innovative ultrasound-based medical devices for treating brain disorders. Its proprietary device, SonoCloud®, is an intracranial ultrasound implant that, when used in conjunction with an intravenous microbubble agent, temporarily opens the blood-brain barrier. This mechanism significantly enhances the delivery of therapeutic molecules to the brain, potentially providing new treatment options for debilitating neurological conditions. Through its technology, Carthera aims to enable healthcare professionals to address challenging brain disorders more effectively.

EBAMed develops a non-invasive ultrasound-based device to monitor and treat heart motion using proton beams. Founded in 2018, the company is based in Geneva, Switzerland.

Escala Medical is focused on developing a pioneering medical device aimed at treating pelvic organ prolapse (POP) in women. The company has created a minimally invasive, incision-free, and mesh-free repair system that addresses the long-standing need for effective POP treatment options. This innovative device allows for a nonsurgical approach that can be performed in outpatient and office settings, ensuring a safe and quick procedure with minimal discomfort for patients. By connecting the vaginal apex to the sacrospinous ligament without incisions, Escala Medical's technology preserves organ functionality while providing a much-needed solution for those affected by POP.

Escala Medical is focused on developing a pioneering medical device aimed at treating pelvic organ prolapse (POP) in women. The company has created a minimally invasive, incision-free, and mesh-free repair system that addresses the long-standing need for effective POP treatment options. This innovative device allows for a nonsurgical approach that can be performed in outpatient and office settings, ensuring a safe and quick procedure with minimal discomfort for patients. By connecting the vaginal apex to the sacrospinous ligament without incisions, Escala Medical's technology preserves organ functionality while providing a much-needed solution for those affected by POP.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center, focused on the development and manufacturing of therapeutic proteins aimed at restoring blood clotting in patients experiencing bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X that can promptly reinstate blood clotting in patients using direct factor Xa anticoagulants, such as rivaroxaban, apixaban, and edoxaban. These anticoagulants, commonly prescribed for the prevention and treatment of thrombosis and stroke, often lead to severe bleeding as a side effect. PseudoXa addresses this critical issue by effectively stopping and preventing bleeding, thereby enhancing the safety of anticoagulant therapy for millions of patients worldwide.

Scandinavian Real Hearts is a medical technology company developing an artificial heart to address the needs of patients awaiting heart transplantation. Its Total Artificial Heart is designed to closely resemble the shape, function, and blood flow of the human heart, with the aim of serving as a bridging solution for transplant candidates.

Tada Group AB, founded in 2016 and headquartered in Stockholm, Sweden, specializes in the manufacturing of medical products, primarily focusing on intravenous solutions. The company offers products such as the Thoor infusion tube, which is designed for efficiency in medical applications. Additionally, Tada Group has developed the ReLink connector, an innovative solution aimed at minimizing complications and costs related to accidental disconnections in IV lines, which is a significant issue in both hospital and homecare environments. Through its product offerings, Tada Group addresses critical challenges in healthcare, enhancing safety and reliability in infusion practices.

Founded in 2019, Arthex Biotech is a Spanish biotechnology company specializing in the development of antisense RNA therapies for genetic diseases. The company, spun off from the University of Valencia, leverages its team's expertise in drug discovery and microRNAs to create innovative treatments.

3DSecret is developing cutting-edge technologies to uncover the stochastic patterns behind metastasis in order to predict the course of cancer.

Founded in 2014, Bluedrop Medical develops an IoT-enabled device for early detection of diabetic foot ulcers. Its home-based system scans patients' feet daily, sends data to the cloud for analysis, and alerts healthcare providers to potential abnormalities, reducing amputation risks.

Smart Immune is a clinical‑stage biotechnology company developing next‑generation hematopoietic stem cell–based biotherapies to improve outcomes for patients with severe diseases. Its flagship program uses T‑cell progenitors (ProTcells) to enable rapid, polyclonal, and safe immune reconstitution after transplantation. The platform integrates targeted conditioning, gene therapy, and genome editing to extend treatment options for inherited blood disorders, blood cancers, and other life‑threatening conditions.

Smart Immune is a clinical‑stage biotechnology company developing next‑generation hematopoietic stem cell–based biotherapies to improve outcomes for patients with severe diseases. Its flagship program uses T‑cell progenitors (ProTcells) to enable rapid, polyclonal, and safe immune reconstitution after transplantation. The platform integrates targeted conditioning, gene therapy, and genome editing to extend treatment options for inherited blood disorders, blood cancers, and other life‑threatening conditions.

Quantune Technologies is a deep tech startup specializing in optics and photonics technology. The company focuses on developing advanced infrared spectrometers that facilitate continuous and non-invasive health monitoring. By miniaturizing traditional laboratory equipment used for molecular analysis into compact modules, Quantune enables both biomedical consumer devices and industrial applications. This innovation allows clients to efficiently conduct real-time monitoring and analysis of chemical compounds and emissions, providing accessible solutions for a range of novel applications.

GrayMatters Health develops digital therapeutics for mental health and related neurological disorders, grounded in self-regulation of brain processes and brain biomarkers. The technology aims to deliver self-neuromodulation treatments that enhance efficacy, safety, and accessibility, enabling healthcare professionals to use neuroscience-based digital interventions within clinical practice and to complement conventional care with non-pharmacological options.

Sunrise is a medical technology company focused on improving the diagnosis and management of sleep disorders, particularly sleep apnea, which affects nearly one billion people worldwide. The company has developed a 3-gram sensor that allows for rapid and accurate at-home diagnosis of sleep conditions, utilizing trigeminal drive analysis to detect respiratory events. This innovative device is clinically validated for use in both adults and children and provides a cost-effective alternative to traditional in-lab sleep studies. Users receive a single-use sensor delivered to their home, which connects easily to their phone for seamless operation. Following the test, Sunrise facilitates consultations with certified sleep doctors or connections to local sleep centers, addressing a critical need in a healthcare landscape where 80% of sleep apnea cases remain undiagnosed.

Sensius is a medical device company based in Rotterdam, Netherlands, founded in 2015. It develops a thermotherapy (hyperthermia) system for head and neck cancer that combines proprietary thermal technology with interactive software and integrated microwave sources. The device is designed by clinicians to tailor treatments, using consumable collars to target the head and neck region. The technology aims to augment standard cancer therapies such as radiotherapy and chemotherapy by improving treatment outcomes and quality of life while reducing associated side effects. Sensius markets its system to oncology clinics and is pursuing CE and FDA clearance, with early interest from potential purchasers as regulatory milestones are approached.

Sensius is a medical device company based in Rotterdam, Netherlands, founded in 2015. It develops a thermotherapy (hyperthermia) system for head and neck cancer that combines proprietary thermal technology with interactive software and integrated microwave sources. The device is designed by clinicians to tailor treatments, using consumable collars to target the head and neck region. The technology aims to augment standard cancer therapies such as radiotherapy and chemotherapy by improving treatment outcomes and quality of life while reducing associated side effects. Sensius markets its system to oncology clinics and is pursuing CE and FDA clearance, with early interest from potential purchasers as regulatory milestones are approached.

Valo Therapeutics is an immunotherapy company focused on developing antigen-coated oncolytic viruses as therapeutic vaccines for cancer treatment. Founded in 2016 and based in Oxford, United Kingdom, with an additional office in Helsinki, Finland, the company utilizes its innovative Valo Tx platform, which includes PeptiCRAd, an engineered human oncolytic adenovirus. This platform is designed to induce systemic anti-tumor T cell responses by transforming oncolytic adenoviruses into targeted, tissue-specific cancer vaccines without requiring the production of multiple genetically modified viruses. Valo Therapeutics is also advancing other neoantigen strategies, including PeptiENV, in collaboration with Professor Vincenzo Cerullo from the University of Helsinki, to enhance therapeutic responses against various cancer types.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

Syntach is a medical technology company focused on developing innovative cardiac support devices aimed at enhancing the care of individuals suffering from heart failure. The company's flagship product is a permanent, active implant designed to restore the impaired movement of the mitral valve while providing natural support to the heart. This device can be inserted using minimally invasive techniques and is smaller than traditional left ventricular assist devices (LVADs), which contributes to a better quality of life for patients and reduces the risk of complications. Syntach's technology is intended to benefit both men and women who require cardiac support.

Ganymed Robotics is a medical device company that develops robotics technologies for orthopedic surgeons, including a therapeutic device designed to improve precision in knee replacement procedures. Founded in 2018 and based in Paris, the company aims to enhance surgical accuracy, reduce operating times, and improve patient outcomes by integrating robotics into the orthopedic workflow.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of major and rare diseases. It employs bioinformatics and artificial intelligence to mitigate risks and reduce costs and development timelines in traditional drug development, while its research and development is guided by a global team of experts in genetics, genomics, immunology, bioinformatics, and drug development.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of major and rare diseases. It employs bioinformatics and artificial intelligence to mitigate risks and reduce costs and development timelines in traditional drug development, while its research and development is guided by a global team of experts in genetics, genomics, immunology, bioinformatics, and drug development.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

iThera Medical develops biomedical imaging technology based on photonic molecular imaging and multispectral optoacoustic tomography (MSOT) for preclinical and clinical applications. The company leverages the photoacoustic effect to visualize and quantify anatomical, functional, and molecular information in vivo, including deep tissue visualization and real-time imaging, enabling non-invasive assessment of tumors and inflammatory diseases. Founded in 2010 as a spin-off from Helmholtz Zentrum München, iThera Medical focuses on advancing MSOT technology for use in preclinical research and clinical trials, supporting researchers and clinicians in obtaining deeper insights into biological processes without invasive procedures.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

Founded in 2018, Resistell develops and markets a diagnostic device for phenotypic antibiotic susceptibility testing. Its unique method detects movement caused by living bacterial cells to determine bacterial resistance to antibiotics.

FOx Biosystems is a biotechnology company focused on enhancing biomolecular interaction analysis for life science research and industry. Founded in 2017 by Filip Delport and Jeroen Lammertyn, and based in Temse, Oost-Vlaanderen, Belgium, the company specializes in developing custom applications, including probes and devices, to support various research needs. FOx Biosystems employs real-time, label-free analysis technology that offers significant advantages over traditional biomolecular analysis tools, such as ease of use, speed, and cost-effectiveness. This technology enables healthcare companies and researchers to obtain high-quality biomolecular data, including concentration measurements, affinity data, and kinetic data, ultimately aiming to transform the life sciences sector.

Newronika develops innovative neuro-modulation devices aimed at restoring brain and body functions. The company translates its deep expertise in biosignal decoding into clinical practice, enabling patients to receive targeted stimulation for improved daily activities and enhanced quality of life.

Avatar Medical is a developer of a virtual reality medical platform that creates 3D patient avatars to assist surgeons in visualizing medical images. By generating interactive representations based on medical data, the platform enables clinicians to accurately and instantly access critical clinical information. This innovative approach not only enhances the understanding of surgical options but also facilitates the training of medical fellows and improves patient engagement. Avatar Medical aims to transform how medical professionals interact with imaging data, ultimately contributing to better surgical outcomes and patient care.

VIVAN Therapeutics pioneers personalized cancer therapeutics using innovative assay technology. It licenses technology from the Center for Personalized Cancer Therapeutics at Mount Sinai New York, offering a comprehensive, genomics-based drug screening service enabled by blockchain. The company's approach intelligently designs personalized treatments, combining cancer and non-cancer drugs to reduce toxicity and cost.

Founded in 2018, Axiles Bionics is a Belgian company specializing in the manufacture of robotic ankle-foot prosthetics. Their primary product is a bionic foot designed to enhance mobility for lower limb amputees.

Vigor Medical Technologies Ltd. develops innovative devices for treating chest trauma and managing thoracic/abdominal drainage. Its self-fixation sealing devices prevent lung and heart collapse, reducing fatality rates associated with chest trauma, which affects over 4 million people worldwide annually.

TENSIVE s.r.l. is a biomedical company based in Milan, Italy, founded in 2012. It specializes in the development of innovative prostheses for natural breast reconstruction and augmentation. The company's products utilize biodegradable synthetic biomaterials and feature an internal micro-architecture that mimics blood vessel structures. These vascularized prostheses aim to enhance the quality of life for patients undergoing treatment for breast cancer, offering a solution that reduces the need for recurrent and costly surgical interventions. Through its focus on advanced biomaterials and design, TENSIVE seeks to provide effective and sustainable options for breast reconstruction.

Carmat is a French medtech company that specializes in the development and manufacturing of bioprosthetic artificial hearts. Founded in 2008 and headquartered in Vélizy-Villacoublay, the company creates biocompatible, auto-regulated total artificial hearts designed to closely mimic the human heart's structure, including both right and left ventricles. These devices are intended for patients suffering from chronic terminal heart failure classified as class IV by the New York Heart Association, as well as those experiencing acute terminal heart failure due to massive myocardial infarction. Carmat aims to provide a reliable and innovative therapeutic solution for heart failure patients who are ineligible for transplants and have exhausted other treatment options. In addition to the artificial hearts, the company develops the necessary power supply systems and remote diagnostic systems for these devices.

CorTec specializes in developing innovative medical devices for neuromodulation and brain-computer interfaces. Its flagship product is the CorTec Brain Interchange™ System, featuring flexible electrode arrays and a hermetically sealed electronics unit with custom microchip technology. The system enables permanent brain recordings and stimulation without the need for battery replacement surgery.

Akknatek is an ophthalmology technology company developing postoperative monitoring and treatment solutions for intraocular lenses (IOLs). Its patented lens reviewer aids clinicians in deciding how to manage dislocated IOLs, with the aim of reducing post-operative refractive complications after cataract surgery and lowering the need for additional refractive procedures. The technology is designed to simplify postoperative management and support improved visual outcomes for patients undergoing cataract surgery.

ABCDx is a Geneva-based company that develops and validates biomarker panels and related diagnostics for brain injury care. It aims to identify patients at risk of severe long-term complications after traumatic brain injury or stroke and to educate clinicians on using these tests. The company is building a platform that analyzes brain biomarkers from a finger-prick blood sample to enable rapid, point-of-care diagnosis of brain injuries, supporting timely treatment decisions. Founded in 2014 by researchers from the University of Geneva and related institutes, ABCDx translates biomarker discovery and clinical validation into practical tools for stroke and brain injury management.

NC Biomatrix is a biotechnology company focused on developing non-invasive treatment for chronic back pain caused by degenerative disc disease. Its therapy consists of an injectable viscous gel designed to restore the natural biomechanics of the spine and alleviate the forces underlying lower back pain, providing an alternative treatment option for patients with spine-related pain.

Afon Technology specializes in the development of non-invasive blood glucose monitoring devices aimed at benefiting individuals with diabetes. The company’s innovative technology allows for real-time, pain-free tracking of blood glucose levels, offering features such as continuous detection, potential pre-diabetic identification, and alarm alerts for high and low glucose levels. Users can access trend profiles and time-in-range statistics through a user-friendly app compatible with both iOS and Android systems. Additionally, Afon Technology’s device can transform any smartwatch into a glucose monitoring tool, providing fast and accurate measurements, data logging, and personalized health trends. This approach enhances daily management for diabetics, ultimately reducing the risk of diabetes-related complications.

Gold Standard Phantoms specializes in the development, marketing, and sale of calibration services and devices for quantitative medical imaging, particularly in the realm of MRI technology. The company manufactures cylindrical phantoms that streamline the preparation process by eliminating the need for multiple sample vials, facilitating more efficient calibration. Its offerings include a cloud-based data analysis platform that ensures traceability to standardized values, allowing clinicians, medical physicists, and radiographers to obtain consistent quantitative measurements of diseases across different patients, scanners, and clinical environments. By enhancing the precision of MRI imaging, Gold Standard Phantoms aims to improve diagnostic accuracy and potentially reduce healthcare costs.

Carmat is a French medtech company that specializes in the development and manufacturing of bioprosthetic artificial hearts. Founded in 2008 and headquartered in Vélizy-Villacoublay, the company creates biocompatible, auto-regulated total artificial hearts designed to closely mimic the human heart's structure, including both right and left ventricles. These devices are intended for patients suffering from chronic terminal heart failure classified as class IV by the New York Heart Association, as well as those experiencing acute terminal heart failure due to massive myocardial infarction. Carmat aims to provide a reliable and innovative therapeutic solution for heart failure patients who are ineligible for transplants and have exhausted other treatment options. In addition to the artificial hearts, the company develops the necessary power supply systems and remote diagnostic systems for these devices.

CorWave is a company focused on developing innovative implanted cardiac support devices aimed at improving the quality of life for patients suffering from heart failure. Its flagship product, the CorWave LVAD, employs a unique undulating disc wave pumping mechanism, which replaces traditional high-speed impellers used in current continuous flow rotary pumps. This design significantly reduces trauma to blood, thereby minimizing complications such as clotting and bleeding. The CorWave pump generates a pulsatile flow that closely resembles the natural heartbeat, addressing a key limitation of existing LVADs that provide only continuous flow. Additionally, the device's low power consumption and compact size facilitate its potential for complete implantation, enhanced by a wireless energy transfer system. Through these advancements, CorWave aims to alleviate the burdens associated with heart failure and invasive surgical procedures.

Alesi Surgical Ltd. is a company based in Cardiff, United Kingdom, specializing in the development and commercialization of laparoscopic surgical smoke handling systems. Founded in 2009 as a spin-out from the Welsh Institute for Minimal Access Therapy, Alesi Surgical focuses on creating products that enhance the safety, efficiency, and outcomes of surgical procedures. Its innovative tools are portable and suitable for both laparoscopic and robot-assisted surgeries, utilizing electrostatic precipitation technology to eliminate surgical smoke and maintain a clear visual field during operations. The company distributes its products to hospitals across Europe, the Middle East, New Zealand, and Australia, leveraging its access to experienced surgeons and surgical trainers to identify challenges in surgical procedures and design effective solutions.

timeisbrain is a medical device for improving the diagnostics and prognostics of acute ischaemic stroke

Vésale Pharma collaborates with renowned global research institutions to develop innovative healthcare solutions tailored for diverse populations. Their product portfolio spans dermatology, gastroenterology, women's health, immunity, and pregnancy, aiming to enhance overall well-being without adverse side effects.